Boehringer Ingelheim has signed a major licensing deal with Synaffix for antibody-drug conjugate (ADC) technology, valued at over $1.3 billion.
This agreement focuses on various undisclosed targets and aims to enhance Boehringer’s NBE Therapeutics ADC portfolio.
ADCs are a modern type of cancer treatment that merges the targeting ability of antibodies with the destructive power of chemotherapy. Unlike traditional chemotherapy, which can harm healthy cells, ADCs are designed to specifically attack tumor cells.
As part of this deal, Synaffix will receive an upfront payment, along with potential milestone payments up to $1.3 billion, and royalties on future sales stemming from their partnership.
Lamine Mbow, Boehringer Ingelheim’s research head, shared that they are working on a wide range of ADCs to explore new tumor targets and develop advanced cancer therapies. He emphasized the goal of merging their cancer treatment know-how with Synaffix’s innovative technology to deliver effective solutions for cancer patients.
Synaffix’s platform improves the way antibodies are modified, making it easier for companies to develop ADCs. This technology relies on three main components: GlycoConnect, HydraSpace, and toxSYN, each playing a key role in the process.
Peter van de Sande, Synaffix’s leader, noted that this agreement showcases the successful preclinical tests of their technology.
Last year, Boehringer made several strategic moves, including a $1.3 billion acquisition of Nerio Therapeutics to expand its immuno-oncology efforts. They also partnered with Brainomix to enhance treatment for fibrosing lung disease, reflecting their commitment to advancing healthcare solutions.